Abstract

γδ T cells are a conserved population of lymphocytes that contributes to anti‐tumor responses through its overt type 1 inflammatory and cytotoxic properties. We have previously shown that human γδ T cells acquire this profile upon stimulation with IL‐2 or IL‐15, in a differentiation process dependent on MAPK/ERK signaling. Here, we identify microRNA‐181a as a key modulator of human γδ T cell differentiation. We observe that miR‐181a is highly expressed in patients with prostate cancer and that this pattern associates with lower expression of NKG2D, a critical mediator of cancer surveillance. Interestingly, miR‐181a expression negatively correlates with an activated type 1 effector profile obtained from in vitro differentiated γδ T cells and miR‐181a overexpression restricts their levels of NKG2D and TNF‐α. Upon in silico analysis, we identify two miR‐181a candidate targets, Map3k2 and Notch2, which we validate via overexpression coupled with luciferase assays. These results reveal a novel role for miR‐181a as critical regulator of human γδ T cell differentiation and highlight its potential for manipulation of γδ T cells in next‐generation immunotherapies.

Highlights

  • Despite the recent advances in therapeutic strategies against cancer, early tumor recurrence and novel metastasis formation indicate resistance to current treatments

  • We investigated potential associations between miRNA expression patterns and cd T cell dysfunction in metastatic cancer patients compared to healthy controls

  • We show that miR-181a overexpression impairs human cd T cell differentiation into TNF-a + effectors, while reducing the expression of natural killer group 2 member D (NKG2D)

Read more

Summary

Introduction

Despite the recent advances in therapeutic strategies against cancer, early tumor recurrence and novel metastasis formation indicate resistance to current treatments This urges the development of alternative treatments for advanced stages of the disease. Cd T cells possess multiple anti-tumor characteristics, making them promising candidates to be used in cellular and combination therapies (Gentles et al, 2015; Silva-Santos et al, 2015, 2019) They provide IFN-cassociated type 1 responses against cancer and express critical determinants of tumor cell recognition, including their signature cd TCR and a variety of NK cell receptors (NKRs), among which the natural killer group 2 member D (NKG2D) is of utmost importance (Lanca et al, 2010; Correia et al, 2013; Silva-Santos et al, 2015; Wu et al, 2019). These limitations stress the need to restore or enhance cd T cell type 1 inflammatory and cytotoxic properties in future immunotherapeutic approaches

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call